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Abstract
Background: The LiGHT trial (Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial) is a
multicentre randomised controlled trial of two treatment pathways for patients who are newly diagnosed with
open-angle glaucoma (OAG) and ocular hypertension (OHT). The main hypothesis for the trial is that lowering
intraocular pressure (IOP) with selective laser trabeculoplasty (SLT) as the primary treatment (‘Laser-1st’) leads
to a better health-related quality of life than for those started on IOP-lowering drops as their primary treatment
(‘Medicine-1st’) and that this is associated with reduced costs and improved tolerability of treatment. This paper
describes the statistical analysis plan for the study.
Methods/Design: The LiGHT trial is an unmasked, multi-centre randomised controlled trial. A total of 718 patients
(359 per arm) are being randomised to two groups: medicine-first or laser-first treatment. Outcomes are recorded
at baseline and at 6-month intervals up to 36 months. The primary outcome measure is health-related quality of
life (HRQL) at 36 months measured using the EQ-5D-5L. The main secondary outcome is the Glaucoma Utility
Index. We plan to analyse the patient outcome data according to the group to which the patient was originally
assigned. Methods of statistical analysis are described, including the handling of missing data, the covariates used
in the adjusted analyses and the planned sensitivity analyses.
Trial registration: The trial was registered with the ISRCTN register on 23/07/2012, number ISRCTN32038223.
Keywords: Ophthalmology, open-angle glaucoma, ocular hypertension, randomised clinical trial, statistical
analysis plan
Update
Background
Glaucoma is a common, irreversible, optic neuropathy
that affects the vision of predominantly older adults and
slowly progresses over a period of years. In the United
Kingdom glaucoma affects more than half a million indi-
viduals, and more than a quarter a million are over the
age of 65 [1]. Glaucoma significantly reduces the quality
of life, which is worse with more severe field loss [2–5].
Ocular hypertension (OHT) is a state of raised intraoc-
ular pressure (IOP) without optic nerve damage, which
progresses to open-angle glaucoma (OAG) in some pa-
tients [6, 7]. Approximately 1.2 million individuals have
raised IOP in the UK [8].
Progressive visual loss can be halted or slowed at all
stages of glaucoma. IOP is the only modifiable risk factor
proven to alter the disease course and thus the associ-
ated morbidity. Laser, medicines and surgery can all suc-
cessfully reduce IOP [9–13]. If medical treatment is
selected, the installation of drops needs to be lifelong.
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Surgery, while effective, carries significant operative risks
and is usually reserved for those who continue to lose
vision despite other treatments. It also has a significant
failure rate, often causes permanent ocular discomfort
and rarely chronic pain [14, 15].
Initial treatment with laser trabeculoplasty (LT) poten-
tially offers a ‘drop-free window’ of several years, removes
concerns about compliance and probably reduces the need
for multiple drops even years later. Even when insufficient
as a sole therapy, LT reduces the intensity of subsequent
medical treatment and, possibly, the need for later surgery.
More effective long-term IOP control in glaucoma leads
to better visual outcomes and less blindness. Drop usage
is itself associated with poorer HRQL in glaucoma patients
through their side effects, the burden of instilling them
several times a day and the need for hospital visits [16]. A
single outpatient treatment is likely to be more acceptable
to patients than daily self-administration of eye-drops for
many years.
The ‘LiGHT’ (Laser-1st versus Drops-1st for Glaucoma
and Ocular Hypertension) Trial is a multi-centre rando-
mised controlled trial comparing health-related quality of
life in patients with newly diagnosed open-angle glaucoma
or ocular hypertension. The objective of this study is to
establish whether initial treatment with selective laser
trabeculoplasty (SLT) of patients with newly diagnosed
open-angle glaucoma or ocular hypertension is superior
to the current standard initial treatment with topical
medication alone in terms of better health-rlated quality
of life (HRQL) at 3 years; lower cost; equally good
intra-ocular pressure control with less need for topical
medication and better patient tolerance.
To prevent outcome reporting bias and data-driven
analysis results, the International Conference on Har-
monisation (ICH) guidelines state that the primary ana-
lysis should be pre-specified [17]. Here, we describe the
statistical analysis plan that will be used to produce the
main trial results. This plan has been finalised while
the data collection in the LiGHT trial is still on-going.
Full details regarding the rationale and design of the
study are given in the study protocol.
Study design
The LiGHT trial is an unmasked, multi-centre, randomised
controlled trial of initial selective laser trabeculoplasty
versus conventional medical therapy.
Patients have been recruited from six centres in the
UK. After obtaining written informed consent from each
participant, patients are being randomly assigned to ei-
ther medicine-first or laser-first treatment. Participants
are randomised in equal proportion using a web-based
randomisation service provided by a specialist company
to achieve full allocation concealment. Block randomisa-
tion, with random block sizes, is used to randomise at the
level of the patient and is stratified by diagnosis (OHT/
OAG) and treatment centre. The trial duration per partici-
pant is 3 years. Participants will complete questionnaires
at baseline and at 6-month intervals up to and including
3 years.
Main hypothesis
For patients with ocular hypertension (OHT) or open-angle
glaucoma (OAG), use of SLT as the primary treatment
(‘Laser-1st’) to lower IOP is associated with better health-
related quality of life compared to the use of IOP-lowering
drops as the primary treatment (‘Medicine-1st’).
Secondary hypotheses
Patients started on SLT as their primary treatment (‘Laser-
1st’) have reduced costs and improved tolerability of treat-
ment compared to patients started on IOP-lowering drops
as their primary treatment (‘Medicine-1st’).
Sample size
The sample size for the study is 718 participants. This
number of participants is required to detect a difference
of 0.05 on the EQ-5D-5L between the two arms at
36 months, assuming a common standard deviation of
0.19 [18], 90 % power and using a two sample t-test at
the 5 % significance level. This sample size assumes a
15 % loss to follow-up.
Ethics
Ethical approval has been obtained from the City Road
and Hampstead REC (12/LO/0940).
General considerations
Levels of confidence and P values
Statistical tests and confidence intervals will be two-
sided. Estimates of treatment effects will be presented
with 95 % confidence intervals and significance will be
considered at the 5 % level.
Protocol violations and exclusions from the study
All patients will be analysed in the treatment arm to which
they were randomised, and all patients will be included,
whether or not they received the allocated treatment.
Protocol deviations and exclusions, including reasons
for any such exclusions, will be reported for each arm
of the trial.
Unit of analysis
The unit of analysis is the patient. If the patient has both
eyes in the study, we will use the worst eye at baseline
for severity and baseline IOP covariates. The worst eye
is defined using the mean deviation (MD) at baseline,
with the worse eye having the most negative MD. In the
case where the MD is the same in both eyes, to two
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decimal places, we will define the worst eye as the one
with the highest IOP. If the patient only has one eye in-
cluded in the study, we will use the severity and baseline
IOP of this eye.
Unadjusted and adjusted analyses
For each outcome variable, the covariate-adjusted analysis
will be designated the primary analysis. The covariate-
adjusted analysis will incorporate the following covariates:
the randomisation factors (severity and centre), baseline
IOP, the baseline value of the corresponding outcome
and whether the patient has one or two eyes affected at
baseline.
Missing data
In the event of non-response after each follow-up, the
subjects will receive two written reminders and then one
telephone follow-up.
Even with the reminders, some loss to follow-up is ex-
pected over 36 months. The proportion of participants
missing each outcome will be summarised in each arm
and at each time point.
The main analysis of the primary outcome uses the
data at 36 months. If this is missing, we will impute this
missing data using the outcome measured at month 30.
Further analyses based on imputed data will be reported
as part of the sensitivity analyses (described later). The
presentation of all findings will be in accordance with
the latest CONSORT statement.
Interim analyses and stopping rules
Interim analyses may be conducted for the data safety
and monitoring committee (DMEC) if requested as per
the agreed terms of reference, but there are no planned
interim analyses to examine efficacy and hence no ad-
justment to inflate the sample size.
We have not defined stopping/discontinuation rules for
early termination of the trial because the two treatment
pathways are designed to generate equivalent attainment of
treatment targets, with possible differences in treatment-re-
lated HRQL and cost but not vision. No difference in
safety outcomes is expected, and should the data moni-
toring committee request interim analyses, these will
be supplied.
Start of data analysis
The analysis of the main trial data for publication pur-
poses will begin once the final randomised patient has
reached the 36 months follow-up and the data has been
cleaned.
Proposed analyses
Baseline
The baseline variables will be as follows: age, sex, ethnicity,
centre, highest educational achievement, employment,
diagnosis (open-angle glaucoma, ocular hypertension),
intraocular pressure, habitual visual acuity (the vision
obtained using the current spectacle or contact lens
correction), distance visual acuity, refraction, medication
use (statins, systemic beta blockers, systemic calcium
channel blockers, and ace inhibitors), and general clin-
ical factors (asthma, hypertension, diabetes, angina, and
cardiac arrhythmia).
For eye-based characteristics, all eligible eyes will be
described using two approaches: 1) left/right eye and 2)
worst/best eye.
The baseline characteristics of each group will be sum-
marised as the mean and standard deviation for continu-
ous, symmetric variables, medians and inter-quartile ranges
for continuous, skewed variables and frequencies and per-
centages for categorical variables. The baseline summaries
will also be presented by centre. These summaries will
be based on observed observations only and the number
of missing observations will be reported. No significance
testing will be used.
Trial profile
The flow of study participants will be displayed in a
CONSORT diagram. The diagram will include the number
of eligible patients, number of patients agreeing to enter
the trial, then by treatment arm: the number of patients
who are compliant/non-compliant, the number continuing
through the trial, the number withdrawing at each time
point, the number lost to follow-up at each time-point and
the numbers excluded/analysed.
Compliance will be assessed by whether a patient re-
ceived the randomised treatment and how compliant they
were with respect to the prescribed treatment (for example,
taking drops).
Primary outcome
The primary outcome measure is health-related quality of
life (HRQL) measured using the EQ-5D-5L at 36 months.
The EQ-5D-5L is a standardised measure of health status,
applicable to a wide range of health conditions and treat-
ments. Its name means ‘EuroQol- 5 Dimensions - 5 Levels’.
It comprises five dimensions of health: mobility, ability to
provide self-care, ability to undertake usual activities, pain
and discomfort, and anxiety and depressions. The study is
powered to detect a difference between trials arms in the
EQ-5D-5L of 0.05 at 36 months.
The EQ-5D-5L will be analysed using regression methods
(analysis of covariance). This will be an adjusted analysis
using the covariates specified earlier (see General consider-
ations section).
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Secondary outcomes
The secondary outcome measures are as follows: 1)
Glaucoma Utility Index (GUI), 2) Glaucoma Symptom
Scale (GSS), 3) Glaucoma Quality of Life-15 (GQL-15), 4)
objective measures of pathway effectiveness and visual
function 5) side effects and adverse events, and 6)
concordance/compliance.
Details on the secondary outcomes can be seen in
Table 1. Further details can be seen in the protocol
(Version 3.0, 20 May 2015).
The secondary outcomes will be analysed using the ap-
propriate regression methods for the type of outcome.
Results from all secondary analyses will be presented
as estimates with confidence intervals and treated as
exploratory.
Data at all time-points
We will use mixed effect models [19], using all patient
outcome data over the 36-months, to investigate how
the primary and secondary outcomes change over time.
Such models allow analysis of repeated outcome mea-
surements data (recorded every 6 months) while taking
into account the correlation between measurements from
the same patient. By using interaction terms between
randomisation group and time, we will to investigate
differences between groups over time. Regression splines
will be used to explore non-linear trajectories, if such
exist.
We will also use a similar mixed effect model using all
patient data over the 36 months to evaluate the treat-
ment effects at 36 months by using the exact times the
questionnaires were completed.
Lastly, using all the patient data over the 36 months,
we will use a mixed effects model to explore the average
treatment effect over the 36 months.
Analysis of missing data
Potential bias due to missing data will be investigated
by comparing descriptively the baseline characteristics
of the trial participants with complete follow-up measure-
ments to those who have incomplete follow-up or no
outcome data. Reasons for withdrawal from treatment
will be summarised. Patients who are compliant with
their treatment plan will be compared descriptively
with non-compliant patients in terms of their baseline
characteristics.
Analyses of homogeneity
In order to explore the homogeneity (or otherwise) of
the intervention effect on the primary outcome, we will
examine the treatment effect across the following: age
(as a continuous measure); severity of glaucoma (using
the two groups OHT/OAG used during randomisation
process); baseline IOP (as a continuous measure) and
sex. The results from these analyses will be treated as ex-
ploratory. The estimates will be reported descriptively with
95 % confidence intervals. P-values will not be reported.
Sensitivity analyses
The following sensitivity analyses will be performed.
First, we will run sensitivity analyses that adjust for
variables associated with missingness. We will perform
logistic regression analyses (with missing yes or no as
outcome) to identify predictors of missing data. If pre-
dictors associated with both missing data and outcomes
are found, we will re-fit the primary analysis model,
adjusting for these predictors of missingness.
Second, we will use a multiple imputation approach.
The imputation model will include the outcome of interest,
socio-demographic variables and any other variables
potentially related to missingness and health related
Table 1 Secondary outcomes
Outcome Description
Glaucoma Utility Index (GUI) A glaucoma-specific treatment-related quality of life specifically designed to capture the impact of
glaucoma treatment and disease severity on HRQL. This is the main secondary outcome.
Glaucoma Symptom Scale (GSS) A patient-reported disease and treatment related symptoms questionnaire.
Glaucoma Quality of Life-15 (GQL-15) A patient-reported visual functioning questionnaire.
Client Services Receipt Inventory (CSRI) A validated method of collecting healthcare cost data. This data will be analysed by the health
economists.
Objective measure of pathway
effectiveness
Efficacy and intensity of the treatment pathways will be assessed at 3 years.
Concordance/Compliance A pair of questions will be asked about drop usage and compliance: 1) ‘Over the past month, what
percentage of your drops do you think you took correctly?’ 2) On a Likert scale, participants will be asked
to respond to the following statement): ‘I’m the sort of person who follows doctors’ orders exactly’.
Adverse events Adverse events possibly associated with treatment will be recorded. Participants will be asked about
possible treatment-related side effects using a simple standardised series of closed and open questions
at each visit.
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quality of life (HRQL). The imputations will be performed
separately by treatment arm.
The number of clinic visits, intensity of treatment and
treatment compliance will be explored. If necessary, sen-
sitivity analyses adjusting for these factors will be carried
out. For example, in addition to the primary analysis, we
may perform analysis using the ‘per-protocol’ approach.
Health economic analyses
As stated in the trial protocol, there will also be health
economic analyses. The details of these analyses are doc-
umented separately.
Current trial status
Recruitment has now finished. The final participant will
be followed up in October 2017.
Abbreviations
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